# Melanoma and MAPK Pathways
**Type:** Topics
**Canonical URL:** https://scholariq.org/topics/melanoma-and-mapk-pathways/
## Facts
| Field | Value |
| --- | --- |
| Description | This cluster of papers focuses on the mammalian MAP kinase signaling pathways, particularly their role in cancer, with a specific emphasis on melanoma. It covers the genetic mutations, targeted therapies, resistance mechanisms, and the impact of MAP kinase pathways on cell proliferation and immune response. |
| Domain | Life Sciences |
| Field | Biochemistry, Genetics and Molecular Biology |
| OpenAlex ID | t11533 |
| Works | 188 |
## Topic papers all
Showing 15 of 188.
- [The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity](https://scholariq.org/papers/the-cancer-cell-line-encyclopedia-enables-predictive-modelling-of-anticancer/)
- [Final Version of 2009 AJCC Melanoma Staging and Classification](https://scholariq.org/papers/final-version-of-2009-ajcc-melanoma-staging-and-classification/)
- [Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma](https://scholariq.org/papers/ipilimumab-plus-dacarbazine-for-previously-untreated-metastatic-melanoma/)
- [BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis](https://scholariq.org/papers/bay-43-9006-exhibits-broad-spectrum-oral-antitumor-activity-and-targets-the-raf/)
- [Genomic Classification of Cutaneous Melanoma](https://scholariq.org/papers/genomic-classification-of-cutaneous-melanoma/)
- [Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children](https://scholariq.org/papers/efficacy-of-larotrectinib-in-i-trk-i-fusion-positive-cancers-in-adults-and/)
- [Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/nivolumab-versus-chemotherapy-in-patients-with-advanced-melanoma-who-progressed/)
- [Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma](https://scholariq.org/papers/final-version-of-the-american-joint-committee-on-cancer-staging-system-for/)
- [Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System](https://scholariq.org/papers/prognostic-factors-analysis-of-17-600-melanoma-patients-validation-of-the/)
- [Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.](https://scholariq.org/papers/interferon-alfa-2b-adjuvant-therapy-of-high-risk-resected-cutaneous-melanoma-the/)
- [Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma](https://scholariq.org/papers/adjuvant-pembrolizumab-versus-placebo-in-resected-stage-iii-melanoma/)
- [Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs](https://scholariq.org/papers/using-multiplexed-assays-of-oncogenic-drivers-in-lung-cancers-to-select-targeted/)
- [Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer](https://scholariq.org/papers/encorafenib-binimetinib-and-cetuximab-in-i-braf-i-v600e-mutated-colorectal/)
- [Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF](https://scholariq.org/papers/kinase-dead-braf-and-oncogenic-ras-cooperate-to-drive-tumor-progression-through/)
- [Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability](https://scholariq.org/papers/multiple-ras-dependent-phosphorylation-pathways-regulate-myc-protein-stability/)
## Topic primary papers
Showing 15 of 58.
- [Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma](https://scholariq.org/papers/ipilimumab-plus-dacarbazine-for-previously-untreated-metastatic-melanoma/)
- [BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis](https://scholariq.org/papers/bay-43-9006-exhibits-broad-spectrum-oral-antitumor-activity-and-targets-the-raf/)
- [Genomic Classification of Cutaneous Melanoma](https://scholariq.org/papers/genomic-classification-of-cutaneous-melanoma/)
- [Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF](https://scholariq.org/papers/kinase-dead-braf-and-oncogenic-ras-cooperate-to-drive-tumor-progression-through/)
- [Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial](https://scholariq.org/papers/dabrafenib-plus-trametinib-in-patients-with-previously-untreated-brafv600e/)
- [BRAF mutation predicts sensitivity to MEK inhibition](https://scholariq.org/papers/braf-mutation-predicts-sensitivity-to-mek-inhibition/)
- [EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib](https://scholariq.org/papers/egfr-mediated-reactivation-of-mapk-signaling-contributes-to-insensitivity-of-i/)
- [RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors](https://scholariq.org/papers/i-ras-i-mutations-in-cutaneous-squamous-cell-carcinomas-in-patients-treated-with/)
- [The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers](https://scholariq.org/papers/the-genomic-landscape-of-endocrine-resistant-advanced-breast-cancers/)
- [Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma](https://scholariq.org/papers/reversible-and-adaptive-resistance-to-braf-v600e-inhibition-in-melanoma/)
- [Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial](https://scholariq.org/papers/dabrafenib-plus-trametinib-in-patients-with-previously-treated-brafv600e-mutant/)
- [Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer](https://scholariq.org/papers/dynamic-reprogramming-of-the-kinome-in-response-to-targeted-mek-inhibition-in/)
- [Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials](https://scholariq.org/papers/meta-analysis-of-phase-ii-cooperative-group-trials-in-metastatic-stage-iv/)
- [Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF -Mutated Colorectal Cancer](https://scholariq.org/papers/phase-ii-pilot-study-of-vemurafenib-in-patients-with-metastatic-i-braf-i-mutated/)
- [V600E BRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathway](https://scholariq.org/papers/sup-v600e-sup-braf-is-associated-with-disabled-feedback-inhibition-of-raf-mek/)
---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.